Obermatt
See Similar Stocks →

Acumen Pharmaceuticals

NSQ:ABOS · US00509G2093
BiotechnologySmall

360° View

no current rank
Price/Sales—
Price/Earnings10
Price/Book97
Dividend Yield—
Revenue Growth—
Profit Growth48
Capital Growth40
TSR 52w72
Leverage19
Liquidity51
Refinancing7
Combined—
Analyst Opinions100
Pro Holdings23
Opinion Changes50
Market Pulse51

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded1996
Employees64
Websiteacumenpharm.com
ISINUS00509G2093
Last UpdateApr 2, 2026
Index & Theme
NeurologyImmunologyChronic DiseasesCentral Nervous SystemNeuroscienceBiotechnologyHealth DiagnosticsTherapeutics

Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a novel disease-modifying approach to target a key underlying cause of Alzheimer’s disease, or AD. The company is focused on advancing a targeted immunotherapy drug c…

Similar Stocks

The companies this stock is ranked against.

Compare Acumen Pharmaceuticals with its peers
ImageneBio
NAQ:IMA
22
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Monopar Therapeutics
NAQ:MNPR
67
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Voyager Therapeutics
NSQ:VYGR
49
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Xencor
NMQ:XNCR
13
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Eupraxia Pharmaceuticals
TOR:EPRX
—
CountryCanada
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Dyne Therapeutics
NSQ:DYN
34
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →